Alinity m HR HPV
Abbott Molecular, Inc. · Decision date Nov 1, 2023
What did the FDA approve?
FDA approved PMA P230003 for the Alinity m HR HPV, a qualitative in vitro test that detects Human Papillomavirus DNA in cervical specimens collected by a health care professional using an endocervical brush/spatula placed in ThinPrep PreservCyt Solution or an endocervical broom placed in SurePath Preservative Fluid. The test identifies high-risk HPV types 16, 18, and 45 while reporting concurrent detection of other high-risk genotype groups (31/33/52/58) and (35/39/51/56/59/66/68).
The stated indication covers routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing with cytology, and HPV primary screening to assess risk for cervical pre-cancer and cancer. The statement says patients should be followed up in accordance with professional medical guidelines, prior screening results, medical history, and other risk factors. The record does not include supplement type or reason, so no additional change beyond the original approval scope is described.
FDA approval order statement
Alinity m HR HPV is a qualitative in vitro test for the detection of Human Papillomavirus DNA in cervical specimens collected by a health care professional using an endocervical brush/spatula placed in ThinPrep PreservCyt Solution or an endocervical broom placed in SurePath Preservative Fluid. This test identifies high-risk (HR) HPV types 16, 18, 45, while reporting the concurrent detection of the other HR genotypes (31/33/52/58) and (35/39/51/56/59/66/68).Alinity m HR HPV is indicated for use in routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing(adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- Nov 1, 2023
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230003
- Regulatory pathway
- Premarket approval application
- Applicant
- Abbott Molecular, Inc.
- Product code
- MAQ
- Decision code
- APPR
- Decision date
- Nov 1, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Abbott Molecular, Inc.
- Product code
- MAQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230003 received
Application receipt date recorded by FDA.
P230003 · FDA decision
APPR
P230003/S019 · Related supplement
Alinity m HR HPV
Timeline entries are records held by MedtechLedger for P230003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
| Roche Molecular Systems, Inc. | PMA approval | Apr 3, 2020 | FDA | |
COBAS HPV TESTP100020 | Roche Molecular Systems, Inc. | PMA approval | Apr 19, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P230003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



